Followers | 117 |
Posts | 4298 |
Boards Moderated | 0 |
Alias Born | 09/13/2006 |
Thursday, April 13, 2023 12:10:45 PM
Recent IFRX News
- InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference • GlobeNewswire Inc. • 10/31/2024 11:30:00 AM
- InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress • GlobeNewswire Inc. • 09/25/2024 11:30:00 AM
- InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- InflaRx Announces Participation in September Investor Events • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/08/2024 11:35:23 AM
- InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 11:30:00 AM
- InflaRx to Report Second Quarter 2024 Results on August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) • GlobeNewswire Inc. • 06/24/2024 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 09:07:57 PM
- InflaRx Hosts R&D Event Highlighting the Promise of INF904 • GlobeNewswire Inc. • 06/05/2024 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2024 08:15:22 PM
- InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators • GlobeNewswire Inc. • 05/21/2024 06:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 12:43:48 PM
- InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event • GlobeNewswire Inc. • 04/24/2024 11:30:00 AM
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 11:30:00 AM
- InflaRx Appoints Jan Medina as Head of Investor Relations • GlobeNewswire Inc. • 02/22/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 01:00:15 PM
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients • GlobeNewswire Inc. • 01/25/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/04/2024 09:16:17 PM
- InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 • GlobeNewswire Inc. • 01/04/2024 12:00:00 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM